RNA editing in human cancer: review
Status odvoláno Jazyk angličtina Země Dánsko Médium print
Typ dokumentu časopisecké články, odvolaná publikace, přehledy
PubMed
19664125
DOI
10.1111/j.1600-0463.2009.02505.x
PII: APM2505
Knihovny.cz E-zdroje
- MeSH
- adenosindeaminasa chemie genetika metabolismus MeSH
- apolipoprotein B-100 chemie metabolismus MeSH
- apolipoprotein B-48 chemie metabolismus MeSH
- editace RNA genetika fyziologie MeSH
- glutamátové receptory chemie metabolismus MeSH
- lidé MeSH
- messenger RNA chemie metabolismus MeSH
- nádory metabolismus MeSH
- proteiny vázající RNA MeSH
- tyrosinfosfatasy metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- odvolaná publikace MeSH
- přehledy MeSH
- Názvy látek
- ADARB1 protein, human MeSH Prohlížeč
- adenosindeaminasa MeSH
- apolipoprotein B-100 MeSH
- apolipoprotein B-48 MeSH
- glutamátové receptory MeSH
- messenger RNA MeSH
- proteiny vázající RNA MeSH
- tyrosinfosfatasy MeSH
In eukaryotes mRNA transcripts are extensively processed by different post-transcriptional events such as alternative splicing and RNA editing in order to generate many different mRNAs from the same gene, increasing the transcriptome and then the proteome diversity. The most frequent RNA editing mechanism in mammals involves the conversion of specific adenosines into inosines by the ADAR family of enzymes. This editing event can alter the sequence and the secondary structure of RNA molecules, with consequences for final proteins and regulatory RNAs. Alteration in RNA editing has been connected to tumor progression and many other important human diseases. Analysis of many editing sites in various cancer types is expected to provide new diagnostic and prognostic markers and might contribute to early detection of cancer, the monitoring of response to therapy, and to the detection of minimal residual disease.
Citace poskytuje Crossref.org
